EIRs Full Text!

Click here to search inspection documents FULL TEXT!

Searching is free.
No subscription.
No obligation.

Why Full-Text?

You can already search the descriptions of all of FOI’s records…and now, you can search the full text of EIRs, 483s, FDA/Industry correspondence and other inspection-related content for revealing and hard to find information:

• Preparing for your own inspections
• Designing realistic mock audits
• Researching competitors
• Learning about suppliers, clinical investigators, potential acquisitions
• And much more!

  

  

Enter your keyword(s) to search the
descriptions of unpublished FDA FOIA records:

Popular searches include: drug trade or generic names; FDA investigator names, company names, device names or 510(k) numbers & more - see Search Hints for more ideas!

Your results may include Establishment Inspection Reports; Investigator Diaries; 483s; correspondence; 510(k)s (not just summaries!); meeting records;
drug, device & biologic original & supplemental reviews & more.


The Freedom of Information Act (FOIA) requires U.S. agencies to disclose many of their records. FDA's FOIA records usually aren't on the agency website – they're files from the desk drawers of reviewers, investigators, and other officials - and FOI Services has collected over 100,000 of these documents. Contact us at infoFOI@foiservices.com for more information.


Find a Document You Need?
Add it to your cart and download it immediately.


Want Some Advice?
Contact us...our information specialists can explain document
content, help you search, and answer other questions.


Can't Find Something?
Call us at +1-301-975-9400 to place a custom request.

  
Events!

FDA AERs UPDATE: Custom drug adverse event reports from our comprehensive database now cover through September 2018. Details and sample searches are online here.



NOW ONLINE: What are your colleagues & competitors reading? See a list of the unpublished documents we've just received on our New Documents page.



 Free!

Document of the Week...

INDs & the Right to Try: Congressional Backgrounder

This November 2018 Congressional Research Service report summarizes, for members of Congress, the issues involved in expanded drug access for Investigational New Drugs. The document specifically addresses past, current and proposed legislation, FDA-related issues and role in regulating access to INDs, and topics now before Congress, including eligible patients, informed consent, data required from drug sponsrs, costs to patients, and liability protection.

Featured until April 23, 2019. Click here to download.